Pricing
  1. JP-listed companies
  2. Chordia Therapeutics,Inc
  3. Financials
  4. Net income

Chordia Therapeutics,Inc (190A)

Market cap
¥8.9B
P/E ratio
-4.5x
Chordia Therapeutics discovers and develops innovative small-molecule cancer drugs that target RNA regulatory stress in cancer cells for pharmaceutical partners.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndNet income (Million JPY)YoY (%)
Aug 31, 2025-1,786-2.26%
Aug 31, 2024-1,827-918.09%
Aug 31, 2023223-112.55%
Aug 31, 2022-1,779+237.51%
Aug 31, 2021-527-46.04%
Aug 31, 2020-977+90.94%
Aug 31, 2019-512

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat